Overview

Comparison of the Time to Recurrence Between Ranibizumab and Aflibercept

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The investigators compared the time to recurrence after ranibizumab or aflibercept loading in patients with AMD.
Details
Lead Sponsor:
Yokohama City University Medical Center
Collaborator:
Novartis Pharmaceuticals
Treatments:
Ranibizumab